Author

V. Borisevich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 9 Organism:non-human primate· 9 Research Focus:drug response / drug discovery· 2 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

R. W. Cross· 9 shared T. W. Geisbert· 9 shared J. B. Geisbert· 8 shared K. N. Agans· 8 shared D. J. Deer· 6 shared K. A. Fenton· 5 shared A. N. Prasad· 4 shared C. Woolsey· 3 shared

Activity by Year

2018-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersMicrobiology

R. W. Cross

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge

C. Woolsey, R. W. Cross, K. N. Agans, V. Borisevich, D. J. Deer, J. B. Geisbert, C. Gerardi, T. E. Lantham, K. A. Fenton, M. Egan, J. H. Eldridge, T. W. Geisbert, D. Matassov

This paper shows a highly attenuated rVSV-based vaccine protects nonhuman primates against lethal Marburg virus challenge when administered up to 1 week before exposure.

bioRxiv · Jan 22, 2022Microbiology

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus Immunotherapeutic

E. Kuang, R. W. Cross, M. McCavitt-Malvido, D. M. Abelson, V. Borisevich, K. N. Agans, N. Mlakar, A. Marimuthu, D. J. Deer, W. S. Shestowsky, D. Kim, J. B. Geisbert, L. Zeitlin, C. L. Moyer, C. J. Roy, , Z. A. Bornholdt

This study shows that a single intramuscular dose of MBP431, a modified ebolavirus therapeutic, can reverse disease and provide protection in non-human primates.

bioRxiv · Jan 6, 2022Microbiology

Natural history of nonhuman primates after conjunctival exposure to Ebola virus

R. W. Cross, A. N. Prasad, C. Woolsey, K. N. Agans, V. Borisevich, N. S. Dobias, J. E. Comer, D. J. Deer, J. B. Geisbert, A. Rasmussen, W. I. Lipkin, K. A. Fenton, T. W. Geisbert

This study examines the natural history of Ebola virus infection in nonhuman primates after conjunctival exposure, finding that lower doses result in delayed disease and reduced mortality.

bioRxiv · Dec 29, 2021Microbiology

Protective pan-ebolavirus combination therapy by two multifunctional human antibodies

P. Gilchuk, C. D. Murin, R. W. Cross, P. A. Ilinykh, K. Huang, N. Kuzmina, V. Borisevich, K. N. Agans, J. B. Geisbert, R. H. Carnahan, R. S. Nargi, R. E. Sutton, N. Suryadevara, S. J. Zost, R. G. Bombardi, , J. E. Crowe

This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.

bioRxiv · May 2, 2021 · PreprintImmunology

Functional cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein

M. P. Doyle, N. Kose, V. Borisevich, E. Binshtein, M. Amaya, M. Nagel, E. J. Annand, E. Armstrong, R. Bombardi, J. Dong, K. L. Schey, C. C. Broder, L. Zeitlin, E. Kuang, Z. Bornholdt, , J. E. Crowe

This study identifies human monoclonal antibodies that neutralize HeV and NiV by targeting distinct antigenic sites on the receptor binding protein and demonstrates their cooperative binding and synergistic therapeutic effects.

bioRxiv · Feb 17, 2021Immunology

Use of convalescent serum reduces severity of COVID-19 in nonhuman primates

r. cross, A. N. Prasad, V. Borisevich, C. Woolsey, K. N. Agans, D. J. Deer, N. S. Dobias, J. B. Geisbert, K. A. Fenton, T. W. Geisbert

This study shows that convalescent sera with high neutralizing antibody titers reduce SARS-CoV-2 viral load and disease severity in African green monkeys.

bioRxiv · Oct 14, 2020Microbiology

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

B. E. Jones, P. L. Brown-Augsburger, K. S. Corbett, K. Westendorf, J. Davies, T. P. Cujec, C. M. Wiethoff, J. L. Blackbourne, B. A. Heinz, D. Foster, R. E. Higgs, D. Balasubramaniam, L. Wang, R. Bidshahri, L. Kraft, , M. de Vries

LY-CoV555, an anti-spike antibody from a convalescent COVID-19 patient, neutralizes SARS-CoV-2 and protects non-human primates against infection.

bioRxiv · Sep 30, 2020Immunology

Establishment of an African green monkey model for COVID-19

C. B. Woolsey, V. Borisevich, A. N. Prasad, K. N. Agans, D. J. Deer, N. S. Dobias, J. C. Heymann, S. L. Foster, C. B. Levine, L. Medina, K. Melody, J. B. Geisbert, K. A. Fenton, T. W. Geisbert, R. W. Cross

This study establishes an African green monkey model for COVID-19, showing high SARS-CoV-2 replication and severe respiratory disease with lower viral doses than in other NHP species.

bioRxiv · May 17, 2020 · PreprintMicrobiology

Prior vaccination with the rVSV-ZEBOV vaccine does not interfere with but improves the efficacy of postexposure antibody treatment in nonhuman primates exposed to Ebola virus

R. W. Cross, Z. A. Bornholdt, A. N. Prasad, J. B. Geisbert, V. Borisevich, K. N. Agans, D. J. Deer, K. Melody, K. A. Fenton, H. Feldmann, A. Sprecher, T. W. Geisbert

bioRxiv · Apr 1, 2020Microbiology

Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates

Z. A. Bornholdt, A. S. Herbert, C. E. Mire, S. He, R. W. Cross, A. Z. Wec, D. M. Abelson, J. B. Geisbert, R. M. James, M. N. Rahim, W. Zhu, V. Borisevich, L. Banadyga, B. M. Gunn, K. N. Agans, , J. M. Dye

This paper demonstrates that a two-antibody cocktail (MBP134AF) provides broad therapeutic protection against multiple ebolaviruses in ferrets and nonhuman primates.

bioRxiv · Aug 19, 2018Microbiology